Open access
Open access
Powered by Google Translator Translator

RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%

18 Feb, 2021 | 02:34h | UTC

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.